Synapse - Jordan Chervin

Search Within

Jordan Chervin

Results (3)

A risk-adapted study to assess the efficacy of enasidenib and subsequent response-driven addition of azacitidine for newly diagnosed IDH2-mutant AML patients: 3-year follow-up

Meeting Abstract

Stein, E.; Cai, S. F.; Huang, Y.; Dunbar, A.; Baer, M. R.; Stock, W.; Kovacsovics, T.; Blum, W. G.; Schiller, G. J.; Olin, R. L.; more...
Blood (2022)

Fulltext@MSK | Save

Enasidenib (ENA) monotherapy with addition of azacitidine in non-responders is effective in older patients with newly diagnosed IDH2 mutated acute myeloid leukemia (AML): A completed phase 2/1b sub-study of the beat AML master trial

Meeting Abstract

Stein, E. M.; Huang, Y.; Borate, U.; Baer, M. R.; Stock, W.; Kovacsovics, T.; Blum, W.; Schiller, G. J.; Olin, R. L.; Foran, J. M.; more...
Blood (2020)

Fulltext@MSK | Save

Enasidenib is highly active in previously untreated IDH2 mutant AML: Early results from the Beat AML Master Trial

Meeting Abstract

Stein, E. M.; Shoben, A.; Borate, U.; Baer, M. R.; Stock, W.; Patel, P. A.; Kovacsovics, T.; Blum, W.; Vergilio, J. A.; Heerema, N. A.; more...
Blood (2018)

Fulltext@MSK | Save